Suchergebnisse - "Lazaro, Estibaliz"

PubPharm (7)

1

Serious infections in patients with VEXAS syndrome : data from the French VEXAS registry

enthalten in: Annals of the rheumatic diseases | 2024

von de Valence, B. | Delaune, M. | Nguyen, Y. | +61

2

Anifrolumab : first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus

enthalten in: Expert review of clinical immunology | 2024

von Gensous, N. | Lazaro, E. | Blanco, P. | +1

3

Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency

enthalten in: Nature | 2023

von Le Voyer, T. | Parent, A. | Liu, X. | +98

4

Outcomes of targeted treatment in immunocompromised patients with asymptomatic or mild COVID-19 : a retrospective study

enthalten in: Scientific reports | 2023

von Lahouati, M. | Cazanave, C. | Labadie, A. | +47

5

Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases

enthalten in: Rheumatology (Oxford, England) | 2023

von Thomas, M. | Masson, M. | Bitoun, S. | +7

6

Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases

enthalten in: Joint bone spine | 2020

von Richez, C. | Lazaro, E. | Lemoine, M. | +2

CommentIn: Rev Rhum Ed Fr. 2020 May;87(3):143-145. - PMID 32355444

7

enthalten in: Revue du rhumatisme (Ed. francaise : 1993) | 2020

von Richez, C. | Lazaro, E. | Lemoine, M. | +2

CommentOn: Joint Bone Spine. 2020 May;87(3):187-189. - PMID 32321633

1
[1]